Study Comparing Bioavailability of Oral Formulations of Vabicaserin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00541996|
Recruitment Status : Completed
First Posted : October 10, 2007
Last Update Posted : December 5, 2007
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: vabicaserin||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||A Randomized, Open-Label, Single-Dose, 4-Period Crossover, Comparative Bioavailability Study of 3 Sustained- Release Formulations and an Immediate- Release Formulation of Vabicaserin (SCA-136) in Healthy Subjects|
|Study Start Date :||August 2007|
|Actual Study Completion Date :||October 2007|
- Assess the bioavailability of four oral formulations of vabicaserin.
- Obtain additional safety and tolerability data for vabicaserin in healthy male subjects.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00541996
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19148|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|